Evidence map›Paper›PMID 40563402›Full record

ReviewBiomolecules2025

Biochar Utilization in Antimicrobial, Anticancer, and Biosensing Applications: A Review.

Ki Ha Min, Koung Hee Kim, Joo-Hyung Seo, Seung Pil Pack

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ki Ha MinInstitute of Industrial Technology, Korea University, Sejong 30019, Republic of Korea.ORCID 0009-0001-7748-9399
Koung Hee KimDepartment of Biotechnology and Bioinformatics, Korea University, Sejong 30019, Republic of Korea.
Joo-Hyung SeoDepartment of Biotechnology and Bioinformatics, Korea University, Sejong 30019, Republic of Korea.
Seung Pil PackDepartment of Biotechnology and Bioinformatics, Korea University, Sejong 30019, Republic of Korea.

Funding

Korea UniversityNational Research Foundation of Korea RS-2021-NR060107
6 · The paper itself

Abstract

Biochar, a carbonaceous material derived from biomass, has garnered significant attention for its biomedical applications due to its unique physicochemical properties. Recent advances in functionalized and composite biochar materials have enabled their use in antibacterial and anticancer treatments, as well as biosensing technologies. This review highlights recent advances in the use of biochar for antimicrobial, anticancer, and biosensing applications. Derived from plant-, marine-, or animal-based biomass through pyrolysis, biochar can be functionalized with silver nanoparticles, metal oxides, or polymers to enhance its antimicrobial activity. In anticancer research, biochar demonstrates the ability to inhibit cancer cell proliferation, modulate the cell cycle, and deliver targeted therapeutics, showing selective cytotoxicity against specific cancer cell types. Furthermore, biochar-based biosensors, when integrated with biomolecules such as enzymes, DNA, or antibodies, exhibit high sensitivity and specificity, making them suitable for precise disease diagnostics. These findings suggest that biochar holds significant potential as a sustainable biomedical material, offering alternatives to conventional antibiotics, supporting cancer therapy, and enabling sensitive biosensing platforms. Future functionalization strategies may further facilitate its clinical translation and practical applications.

Indexed as

Anti-Infective AgentsAntineoplastic AgentsBiosensing TechniquesCharcoalAnimalsHumansMetal NanoparticlesNeoplasmsAnti-Infective AgentsAntineoplastic AgentsbiocharCharcoalantibioticsanticancerbiocharbiomedical applicationbiosensor

Identifiers

PMID40563402
PMCPMC12190419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.